Unmet needs in the scientific approach to older patients with lymphoma
暂无分享,去创建一个
E. Kimby | B. Coiffier | M. André | E. Zucca | I. Aurer | D. Bron | P. Soubeyran | C. Falandry | C. Bonnet | D. Caballero | A. Bosly
[1] F. Angrilli,et al. Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study , 2018, Hematological oncology.
[2] C. Guillén-Ponce,et al. Where Are We Headed With Research in Frail Elderly Patients With Cancer? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Mathoulin-Pélissier,et al. Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. , 2016, Journal of geriatric oncology.
[4] I. Floriani,et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). , 2015, Journal of geriatric oncology.
[5] G. Colditz,et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. , 2015, Journal of geriatric oncology.
[6] H. Wildiers,et al. Multicenter implementation of geriatric assessment in Belgian patients with cancer: a survey on treating physicians' general experiences and expectations. , 2014, Journal of Geriatric Oncology.
[7] R. Stauder,et al. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.
[8] C. Solid,et al. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy , 2014, Supportive Care in Cancer.
[9] R. Stauder,et al. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy , 2014, Annals of Hematology.
[10] M. D'Andrea,et al. A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. , 2013, Journal of geriatric oncology.
[11] F. Peyrade,et al. Treatment decisions for elderly patients with haematological malignancies: a dilemma. , 2012, The Lancet. Oncology.
[12] G. Lyman,et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.
[13] M. Pfreundschuh. How I treat elderly patients with diffuse large B-cell lymphoma. , 2010, Blood.
[14] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[15] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[16] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[17] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.